SCHEMBL3728919

SCHEMBL3728919

CCCCC/C=C\C/C=C\CCCCCCCCO[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.69
NR5A2 O00482 1/20 0.69
NR5A1 Q13285 1/20 0.69
MAPT P10636 3/20 0.67
RECQL P46063 1/20 0.58
FABP3 P05413 1/20 0.55
MAPK1 P28482 4/20 0.54
MEN1 O00255 2/20 0.54
GMNN O75496 2/20 0.54
LMNA P02545 2/20 0.54
BLM P54132 2/20 0.54
KMT2A Q03164 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
TP53 P04637 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2D6 P10635 2/20 0.54
CYP2C9 P11712 2/20 0.54
ALOX15 P16050 2/20 0.54
NFKB1 P19838 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417340 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL31381152 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL564851 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL31381151 0.97 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL122604 0.97 SMN1; SMN2 (0.73) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL19821335 0.97 SMN1; SMN2 (0.73) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL6811206 0.97 SMN1; SMN2 (0.73) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL18092159 0.92 SMN1; SMN2 (0.66) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL23834444 0.92 NR5A2 (0.83) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT
SCHEMBL10498201 0.92 NR5A2 (0.83) ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7811988-B2 Lipid mixtures for synthetic surfactants CHIESI FARMACEUTICI S.P.A. (IT) 2010-10-12 US claimed
EP-1628634-B1 NOVEL LIPID MIXTURES FOR SYNTHETIC SURFACTANTS CHIESI FARMA SPA (IT) 2009-12-23 EP claimed
US-20080045449-A1 A lipid mixture for synthetic surfactants comprising >40% by weight of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and >10% of polyunsaturated phospholipids; treatment of surfactant deficiencies like infant respiratory distress syndrome (RDS); rheology; low surface tension; fast spreading CHIESI FARMACEUTICI S.P.A. (IT) 2008-02-21 US claimed
EP-3727418-B1 SURFACTANT FORMULATIONS FOR INHALATION MERZ PHARMACEUTICALS LLC (US) 2026-04-08 EP disclosed
EP-3474832-B1 SURFACTANT FORMULATIONS FOR INHALATION MERZ PHARMACEUTICALS LLC (US) 2026-03-18 EP disclosed
US-20250288516-A1 Surfactant Formulations for Inhalation MERZ PHARMACEUTICALS LLC (US) 2025-09-18 US disclosed
US-20250262150-A1 Surfactant Formulations for Inhalation MERZ PHARMACEUTICALS LLC (US) 2025-08-21 US disclosed
US-20240016823-A1 SURFACTANT FORMULATIONS FOR INHALATION MERZ PHARMACEUTICALS, LLC 2024-01-18 US disclosed
US-20210386664-A1 Surfactant Formulations for Inhalation MERZ PHARMACEUTICALS, LLC 2021-12-16 US disclosed
US-20210169794-A1 Surfactant Formulations for Inhalation MERZ PHARMACEUTICALS, LLC 2021-06-10 US disclosed
EP-3474832-A1 SURFACTANT FORMULATIONS FOR INHALATION Civitas Therapeutics, Inc. (US) 2019-05-01 EP disclosed
WO-2017223502-A1 SURFACTANT FORMULATIONS FOR INHALATION CIVITAS THERAPEUTICS, INC. (US) 2017-12-28 WO disclosed
US-7811988-B2 Lipid mixtures for synthetic surfactants CHIESI FARMACEUTICI S.P.A. (IT) 2010-10-12 US disclosed
EP-1628634-B1 NOVEL LIPID MIXTURES FOR SYNTHETIC SURFACTANTS CHIESI FARMA SPA (IT) 2009-12-23 EP disclosed
US-20080045449-A1 A lipid mixture for synthetic surfactants comprising >40% by weight of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and >10% of polyunsaturated phospholipids; treatment of surfactant deficiencies like infant respiratory distress syndrome (RDS); rheology; low surface tension; fast spreading CHIESI FARMACEUTICI S.P.A. (IT) 2008-02-21 US disclosed
EP-1628634-A1 NOVEL LIPID MIXTURES FOR SYNTHETIC SURFACTANTS CHIESI FARMACEUTICI S.p.A. (IT) 2006-03-01 EP disclosed
WO-2004105726-A1 NOVEL LIPID MIXTURES FOR SYNTHETIC SURFACTANTS CHIESI FARMACEUTICI S.P.A. (IT) 2004-12-09 WO disclosed
EP-1481665-A1 Novel lipid mixtures for synthetic surfactants CHIESI FARMACEUTICI S.p.A. (IT) 2004-12-01 EP disclosed